小剂量重组人干扰素α-1b治疗流行性腮腺炎的临床观察

Clinical observation of small dose recombinant human interferon α-1b in the treatment of epidemic parotitis

目的观察小剂量重组人干扰素α-1b治疗流行性腮腺炎的疗效。方法将148例流行性腮腺炎患者随机分为治疗组和对照组：治疗组75例,采用重组人干扰素α-1b 10μg皮下或肌注每日1次,治疗3 d联合利巴韦林注射剂静脉输液[（10~15）mg/（kg·d）]每次日2次至症状消失;对照组73例,采用利巴韦林注射剂静脉输液[（10~15）mg/（kg·d）]每日2次至症状消失。结果 1治疗组总有效率100.0%,显效率58.7%,并发症发生率1.3%,对照组总有效率79.5%,显效率13.7%,并发症发生率24.7%,经统计学分析,差异均有高度统计学意义（P〈0.01）。2治疗组退热时间（28.5±10.4）h,腮腺及颌下淋巴腺肿消退时间（51.5±10.8）h;对照组退热时间（110.5±11.6）h,腮腺及颌下淋巴腺肿消退时间（110.5±11.8）h,差异具有统计学意义（P均〈0.05）。结论小剂量干扰素治疗流行性腮腺炎显效率明显提高,同时可减少并发症发生、及时缓解临床症状及缩短病程也明显优于传统治疗方法。

Objective To observe the curative effects of small dose recombinant human interferon α-lb in the treat- ment of epidemic parotitis. Methods All 148 patients with epidemic parotitis were randomly assigned to treatment group and control group. 75 patients in the treatment group were given subcutaneous injection or intramuscular injec- tion of recombinant human interferon α-lb once a day for 3 days, combined with intravenous drop of ribavirin injection （10-15） mg/（kg.d）, twice a day until the symptoms disappeared. 73 patients in the control group were given intrave- nous drop of ribavirin injection （10-15） mg/（kg·d）, twice a day until the symptoms disappeared. Results ①Total effective rate in the treatment group was 100.0%, significant effective rate was 58.7%, and incidence of complications was 1.3%; total effective rate in the control group was 79.5%, significant effective rate was 13.7%, and the incidence of complications was 24.7%. According to statistically analysis, the differences were all statistically significant （P〈0.01）. ②Time of fever abatement in the treatment group was （28.5±10.4） h, and subsidence time of swelling of parotid gland and submaxillary lymph gland was （51.5±10.8） h. Time of fever abatement in the control group was （110.5±11.6） h, and subsidence time of swelling of parotid gland and submaxillary lymph gland was （1105±11.8） h. The differences were significant （all P〈0.05）. Conclusion Significant rate of small dose interferon in the treatment of epidemic parotitis is significantly higher than that in the control group. Meanwhile, reduction of complications, timely alleviation of clini- cal symptoms and shortening of disease course are significantly better than those in conventional treatment methods.